EPC Stock Analysis: Edgewell Personal Care | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 1.288m USD | 12M Return: 45% | US28035Q1022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.0M
EPS Trend: -66.8%
Qual. Beats: 0
Rev. Trend: -86.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Edgewell Personal Care Company (NYSE: EPC) is a global manufacturer and marketer of personal care products organized into three reporting segments: Wet Shave, Sun and Skin Care, and Feminine Care. The company operates in the Consumer Staples sector, specifically the Personal Care Products sub-industry, and uses a multi-brand portfolio strategy to address distinct product categories.
The Wet Shave segment, the companys largest by historical focus, sells razor systems, disposable razors, and shave preparation products under brands including Schick, Wilkinson Sword, Edge, Skintimate, Billie, and Shave Guard, alongside private label offerings. The Sun and Skin Care segment covers sun care (Banana Boat, Hawaiian Tropic), antibacterial wipes (Wet Ones), and mens grooming lines (Bulldog, Jack Black, Cremo). The Feminine Care segment markets tampons (Playtex, Playtex Sport, Playtex Gentle Glide 360°, o.b.) and pads and liners (Stayfree, Carefree).
Edgewell distributes its products through a direct sales force as well as exclusive and non-exclusive distributors and wholesalers, reaching mass-market, drug, and grocery retail channels typical of consumer staples companies. The company was originally founded in 1772, was formerly known as Energizer Holdings, Inc., and adopted its current name in June 2015 following the spin-off of its battery business. Edgewell is headquartered in Shelton, Connecticut.
- Wet Shave share losses to Gillette and DTC brands pressure sales
- Sun Care revenue rebounds on summer demand and travel recovery
- Input cost inflation and pricing actions squeeze gross margins
| Net Income: -93.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.36 > 1.0 |
| NWC/Revenue: 24.80% < 20% (prev 19.84%; Δ 4.96% < -1%) |
| CFO/TA 0.03 > 3% & CFO 121.2m > Net Income -93.2m |
| Net Debt (898.4m) to EBITDA (67.3m): 13.35 < 3 |
| Current Ratio: 1.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.6m) vs 12m ago -2.92% < -2% |
| Gross Margin: 40.87% > 18% (prev 42.16%; Δ -1.29% > 0.5%) |
| Asset Turnover: 55.93% > 50% (prev 58.10%; Δ -2.17% > 0%) |
| Interest Coverage Ratio: -0.22 > 6 (EBIT TTM -14.9m / Interest Expense TTM 68.7m) |
| A: 0.14 (Total Current Assets 1.11b - Total Current Liabilities 603.6m) / Total Assets 3.54b |
| B: 0.28 (Retained Earnings 1.00b / Total Assets 3.54b) |
| C: -0.00 (EBIT TTM -14.9m / Avg Total Assets 3.66b) |
| D: 0.70 (Book Value of Equity 1.46b / Total Liabilities 2.08b) |
| Altman-Z'' = 2.58 = A |
| DSRI: 0.93 (Receivables 188.7m/218.9m, Revenue 2.05b/2.20b) |
| GMI: 1.03 (GM 42.16% / 40.87%) |
| AQI: 0.94 (AQ_t 0.60 / AQ_t-1 0.64) |
| SGI: 0.93 (Revenue 2.05b / 2.20b) |
| TATA: -0.06 (NI -93.2m - CFO 121.2m) / TA 3.54b) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of October 29, 2026, the stock is trading at USD 27.67 with a total of 392,645 shares traded. Over the past week, the price has changed by +2.56%, over one month by -2.19%, over three months by -1.59% and over the past year by +45.02%.
Current recommended Stop Loss: 26.30 (which is 5% or 1.4 ATR below the current price).
Edgewell Personal Care has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold EPC.
- StrongBuy: 2
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.5 | 13.8% |
P/E Forward = 13.6426
P/S = 0.5741
P/B = 0.8824
P/EG = 2.8727
Revenue TTM = 2.05b USD
EBIT TTM = -14.9m USD
EBITDA TTM = 67.3m USD
Long Term Debt = 1.25b USD (from longTermDebt, last quarter)
Short Term Debt = 34.2m USD (from shortTermDebt, last quarter)
Debt = 1.30b USD (from shortLongTermDebtTotal, last quarter) + Leases 16.3m
Net Debt = 898.4m USD (calculated: Debt 1.30b - CCE 397.1m)
Enterprise Value = 2.19b USD (1.29b + Debt 1.30b - CCE 397.1m)
Interest Coverage Ratio = -0.22 (Ebit TTM -14.9m / Interest Expense TTM 68.7m)
EV/FCF = 41.73x (Enterprise Value 2.19b / FCF TTM 52.4m)
FCF Yield = 2.40% (FCF TTM 52.4m / Enterprise Value 2.19b)
FCF Margin = 2.56% (FCF TTM 52.4m / Revenue TTM 2.05b)
Net Margin = -4.55% (Net Income TTM -93.2m / Revenue TTM 2.05b)
Gross Margin = 40.87% ((Revenue TTM 2.05b - Cost of Revenue TTM 1.21b) / Revenue TTM)
Gross Margin QoQ = 42.54% (prev 43.43%)
Tobins Q-Ratio = 0.62 (Enterprise Value 2.19b / Total Assets 3.54b)
Interest Expense / Debt = 5.30% (Interest Expense 68.7m / Debt 1.30b)
Taxrate = 31.67% (5.70m / 18.0m)
NOPAT = -10.2m (EBIT -14.9m * (1 - 31.67%)) [loss with tax shield]
Current Ratio = 1.84 (Total Current Assets 1.11b / Total Current Liabilities 603.6m)
Debt / Equity = 0.89 (Debt 1.30b / totalStockholderEquity, last quarter 1.46b)
Debt / EBITDA = 13.35 (Net Debt 898.4m / EBITDA 67.3m)
Debt / FCF = 17.15 (Net Debt 898.4m / FCF TTM 52.4m)
Total Stockholder Equity = 1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.54% (Net Income -93.2m / Total Assets 3.54b)
RoE = -6.27% (Net Income TTM -93.2m / Total Stockholder Equity 1.49b)
RoCE = -0.55% (EBIT -14.9m / Capital Employed (Equity 1.49b + L.T.Debt 1.25b))
RoIC = -0.36% (negative operating profit) (NOPAT -10.2m / Invested Capital 2.86b)
WACC = 4.92% (E(1.29b)/V(2.58b) * Re(6.22%) + D(1.30b)/V(2.58b) * Rd(5.30%) * (1-Tc(0.32)))
Discount Rate = 6.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.29 | Cagr: -3.25%
[DCF] Terminal Value 77.97% ; FCFF base≈48.5m ; Y1≈55.6m ; Y5≈81.9m
[DCF] Fair Price = 7.23 (EV 1.23b - Net Debt 898.4m = Equity 333.4m / Shares 46.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -66.75 | EPS CAGR: -11.02% | SUE: 0.68 | # QB: 0
Revenue Correlation: -86.09 | Revenue CAGR: -3.06% | SUE: -0.30 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.02 | Chg30d=N/A | Revisions=+57% | Analysts=5
EPS current Year (2026-09-30): EPS=1.93 | Chg30d=+0.00% | Revisions=+30% | GrowthEPS=-23.6% | GrowthRev=-9.9%
EPS next Year (2027-09-30): EPS=1.99 | Chg30d=-1.12% | Revisions=-50% | GrowthEPS=+3.4% | GrowthRev=+0.9%
[Analyst] Revisions Ratio: +10% (up=10, down=8)